| accession | NYESO1 |
| Source | DNA sequence encoding the Human (HLA-A*02:01) AA25-305 [accession# P04439] and the B2M protein AA2-119 [accession# P61769], fused to the mutant NY-ESO-1 epitope SLLMWITQC .This complex includes a C terminal polyHis AVI tag and was expressed in HEK cells, The teramer conformation was achieved through biotinylation of the monomer and then covalently binding the monomers via an avidin biotin reaction. |
| Molecular weight | Recombinant HLA-A/NY-ESO-1 has a calculated mass of approximately 250kDa. Due to glycosylation migrates as an approximately 260 kDa protein under reducing conditions in SDS-PAGE. |
| Purity | purity was determined to be >95% by nonreducing PAGE and HPLC (see below methods) |
| Endotoxin | Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg). |
| Presentation | Recombinant (HLA-A*02:01) NY-ESO1 was lyophilized from 0.2 µm filtered PBS solution pH7.4 |
| Reconstitution | A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers. |
| Storage | The lyophilized protein is stable for at least 2 years from date of receipt at -20° C. |
| Usage | This product is for research purposes only.It may not be used for therapeutics or diagnostic purposes. |
Methods
HLA-A*02:01 NY-ESO-1 peptide complex tetramer SPR
|
HLA-A*02:01 NY-ESO-1 peptide complex tetramer ELISA
|
HLA-A*02:01 NY-ESO-1 peptide complex tetramer PAGE
|
NY-ESO-1 (HLA-A*02:01) HPLC
|